BR112014031730A2 - entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1 - Google Patents
entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1Info
- Publication number
- BR112014031730A2 BR112014031730A2 BR112014031730A BR112014031730A BR112014031730A2 BR 112014031730 A2 BR112014031730 A2 BR 112014031730A2 BR 112014031730 A BR112014031730 A BR 112014031730A BR 112014031730 A BR112014031730 A BR 112014031730A BR 112014031730 A2 BR112014031730 A2 BR 112014031730A2
- Authority
- BR
- Brazil
- Prior art keywords
- chemical entities
- pde1
- compositions
- disorders
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1 resumo são descritos aqui compostos e entidades químicas da fórmula (i), métodos de síntese dos mesmos, composições que compreendem os mesmos e seu uso no tratamento de várias doenças e distúrbios, incluindo déficits cognitivos associados a doenças e distúrbios do snc. 1/1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661091P | 2012-06-18 | 2012-06-18 | |
US61/661,091 | 2012-06-18 | ||
PCT/US2013/046403 WO2013192225A1 (en) | 2012-06-18 | 2013-06-18 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014031730A2 true BR112014031730A2 (pt) | 2017-06-27 |
BR112014031730B1 BR112014031730B1 (pt) | 2023-05-16 |
Family
ID=49756458
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014031730-5A BR112014031730B1 (pt) | 2012-06-18 | 2013-06-18 | Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso |
BR112014031731-3A BR112014031731B1 (pt) | 2012-06-18 | 2013-06-18 | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014031731-3A BR112014031731B1 (pt) | 2012-06-18 | 2013-06-18 | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos |
Country Status (18)
Country | Link |
---|---|
US (7) | US9499562B2 (pt) |
EP (3) | EP2861605B1 (pt) |
JP (2) | JP6129960B2 (pt) |
KR (2) | KR102087756B1 (pt) |
CN (2) | CN104583217B (pt) |
AU (3) | AU2013277294C1 (pt) |
BR (2) | BR112014031730B1 (pt) |
CA (2) | CA2877149C (pt) |
DK (2) | DK2861603T3 (pt) |
ES (2) | ES2715325T3 (pt) |
HK (2) | HK1208023A1 (pt) |
IL (2) | IL236232A (pt) |
IN (2) | IN2015DN00335A (pt) |
MX (2) | MX359615B (pt) |
NZ (2) | NZ703949A (pt) |
RU (2) | RU2653054C2 (pt) |
SG (3) | SG10201703253XA (pt) |
WO (2) | WO2013192229A1 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2305353A1 (en) * | 2000-08-10 | 2011-04-06 | Cold Spring Harbor Laboratory | Augmented cognitive training |
BR112014031730B1 (pt) * | 2012-06-18 | 2023-05-16 | Dart Neuroscience (Cayman) Ltd | Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso |
JP6396230B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
JP6396229B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
JP6396231B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
GB201406486D0 (en) * | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
WO2017046603A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds and new uses thereof |
AR107456A1 (es) | 2016-02-12 | 2018-05-02 | Lilly Co Eli | Inhibidor de pde1 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
JOP20170164A1 (ar) | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
CN109843884B (zh) * | 2016-10-18 | 2022-03-04 | H.隆德贝克有限公司 | 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 |
US10912773B2 (en) | 2016-10-28 | 2021-02-09 | H. Lundbeck A/S | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors |
AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
JP7111720B2 (ja) | 2016-12-28 | 2022-08-02 | ダート・ニューロサイエンス・エルエルシー | Pde2阻害剤としての置換ピラゾロピリミジノン化合物 |
WO2018125746A1 (en) * | 2016-12-30 | 2018-07-05 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
US10919898B2 (en) * | 2017-02-23 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Medical use of compound III |
AR112457A1 (es) | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
AR112346A1 (es) | 2017-08-10 | 2019-10-16 | Lilly Co Eli | Derivados de [1,2,4]triazolo |
DK3717488T3 (da) | 2017-11-27 | 2021-12-13 | Dart Neuroscience Llc | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer |
GB2575490A (en) * | 2018-07-12 | 2020-01-15 | Recordati Ind Chimica E Farmaceutica Spa | P2X3 receptor antagonists |
EP4017858A4 (en) * | 2019-08-22 | 2023-09-27 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
CN112778311A (zh) * | 2019-11-01 | 2021-05-11 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3046366A1 (de) * | 1980-12-09 | 1982-07-08 | Bayer Ag, 5090 Leverkusen | Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung |
DE3146599A1 (de) | 1981-11-25 | 1983-07-07 | Basf Ag, 6700 Ludwigshafen | Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
EP0181282A1 (de) | 1984-10-01 | 1986-05-14 | Ciba-Geigy Ag | Triazolochinazolinverbindungen |
EP0217748B1 (en) | 1985-09-30 | 1991-02-06 | Ciba-Geigy Ag | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
JPS62135475A (ja) * | 1985-09-30 | 1987-06-18 | チバ−ガイギ− アクチエンゲゼルシヤフト | 2−置換−e−融合−〔1,2,4〕トリアゾロ−〔1,5−C〕ピリミジン |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
FR2659329B1 (fr) | 1990-03-09 | 1994-06-03 | Adir | Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
WO1999038504A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
ES2166270B1 (es) | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. |
DE10012373A1 (de) * | 2000-03-14 | 2001-09-20 | Dresden Arzneimittel | Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion |
US8153646B2 (en) | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
EP2305353A1 (en) | 2000-08-10 | 2011-04-06 | Cold Spring Harbor Laboratory | Augmented cognitive training |
FR2897061B1 (fr) * | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
EP2023729B1 (en) * | 2006-06-06 | 2016-05-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2008118414A1 (en) * | 2007-03-28 | 2008-10-02 | Merck & Co., Inc. | Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators |
EP2152275A4 (en) | 2007-05-15 | 2011-08-03 | Helicon Therapeutics Inc | METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA (SIARN) |
JP5265687B2 (ja) * | 2007-09-26 | 2013-08-14 | ジーイー・ヘルスケア・バイオサイエンス・バイオプロセス・コーポレイション | 三次元の使い捨てバイオリアクター |
CA2845454C (en) | 2007-12-06 | 2017-02-07 | Takeda Pharmaceutical Company Limited | Organic compounds useful as inhibitors of phosphodiesterase 1 |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
KR20110095881A (ko) | 2008-12-06 | 2011-08-25 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
WO2010065153A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
US11464781B2 (en) | 2009-02-25 | 2022-10-11 | Intra-Cellular Therapies, Inc. | PDE1 inhibitors for ophthalmic disorders |
JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
WO2011153136A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2011153135A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2011153138A1 (en) * | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
BR112014031730B1 (pt) * | 2012-06-18 | 2023-05-16 | Dart Neuroscience (Cayman) Ltd | Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso |
-
2013
- 2013-06-18 BR BR112014031730-5A patent/BR112014031730B1/pt active IP Right Grant
- 2013-06-18 CN CN201380043254.5A patent/CN104583217B/zh active Active
- 2013-06-18 JP JP2015518523A patent/JP6129960B2/ja active Active
- 2013-06-18 US US14/408,927 patent/US9499562B2/en active Active
- 2013-06-18 CA CA2877149A patent/CA2877149C/en active Active
- 2013-06-18 BR BR112014031731-3A patent/BR112014031731B1/pt active IP Right Grant
- 2013-06-18 RU RU2015100213A patent/RU2653054C2/ru active
- 2013-06-18 EP EP13807708.6A patent/EP2861605B1/en active Active
- 2013-06-18 US US14/408,942 patent/US9284335B2/en active Active
- 2013-06-18 CN CN201380043291.6A patent/CN104583213B/zh active Active
- 2013-06-18 IN IN335DEN2015 patent/IN2015DN00335A/en unknown
- 2013-06-18 ES ES13807565T patent/ES2715325T3/es active Active
- 2013-06-18 NZ NZ703949A patent/NZ703949A/en unknown
- 2013-06-18 SG SG10201703253XA patent/SG10201703253XA/en unknown
- 2013-06-18 NZ NZ703950A patent/NZ703950A/en unknown
- 2013-06-18 JP JP2015518522A patent/JP6240180B2/ja active Active
- 2013-06-18 AU AU2013277294A patent/AU2013277294C1/en active Active
- 2013-06-18 MX MX2014015737A patent/MX359615B/es active IP Right Grant
- 2013-06-18 ES ES18213541T patent/ES2904267T3/es active Active
- 2013-06-18 SG SG11201408395WA patent/SG11201408395WA/en unknown
- 2013-06-18 IN IN334DEN2015 patent/IN2015DN00334A/en unknown
- 2013-06-18 DK DK13807565.0T patent/DK2861603T3/en active
- 2013-06-18 SG SG11201408397SA patent/SG11201408397SA/en unknown
- 2013-06-18 US US13/920,974 patent/US9175010B2/en active Active
- 2013-06-18 DK DK18213541.8T patent/DK3489238T3/da active
- 2013-06-18 MX MX2014015740A patent/MX357320B/es active IP Right Grant
- 2013-06-18 KR KR1020157001117A patent/KR102087756B1/ko active IP Right Grant
- 2013-06-18 EP EP13807565.0A patent/EP2861603B1/en active Active
- 2013-06-18 AU AU2013277298A patent/AU2013277298B2/en active Active
- 2013-06-18 KR KR1020157001198A patent/KR102191816B1/ko active IP Right Grant
- 2013-06-18 CA CA2877146A patent/CA2877146C/en active Active
- 2013-06-18 WO PCT/US2013/046415 patent/WO2013192229A1/en active Application Filing
- 2013-06-18 EP EP18213541.8A patent/EP3489238B8/en active Active
- 2013-06-18 WO PCT/US2013/046403 patent/WO2013192225A1/en active Application Filing
- 2013-06-18 RU RU2015100209A patent/RU2659779C2/ru active
-
2014
- 2014-12-14 IL IL236232A patent/IL236232A/en active IP Right Grant
- 2014-12-14 IL IL236233A patent/IL236233A/en active IP Right Grant
-
2015
- 2015-09-02 HK HK15108586.6A patent/HK1208023A1/xx unknown
- 2015-09-02 HK HK15108624.0A patent/HK1208024A1/xx unknown
- 2015-09-14 US US14/853,856 patent/US9533996B2/en active Active
-
2016
- 2016-11-17 US US15/354,804 patent/US10092575B2/en active Active
- 2016-12-29 US US15/394,058 patent/US10105367B2/en active Active
-
2017
- 2017-12-07 AU AU2017272245A patent/AU2017272245B2/en active Active
-
2018
- 2018-10-18 US US16/164,726 patent/US10376514B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014031730A2 (pt) | entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1 | |
EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
BR112013031098A2 (pt) | halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2 | |
BR112015017997A8 (pt) | amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso | |
EA201170963A1 (ru) | Ингибиторы поли(адф-рибозо)полимеразы (parp) | |
BR112013031510A2 (pt) | [1,3]oxazinas | |
EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
BR112014009851A2 (pt) | moduladores de receptor de nmda e usos dos mesmos | |
UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
BR112015032902A8 (pt) | compostos de heteroarila, seus usos e composições farmacêuticas | |
BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
PH12015502365B1 (en) | Bace1 inhibitors | |
CN107406464A8 (zh) | 精氨酸酶抑制剂及其治疗用途 | |
PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
BR112017012588B8 (pt) | Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico | |
BR112017015474A2 (pt) | inibidores de bace1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2013, OBSERVADAS AS CONDICOES LEGAIS |